抗血小板治疗对血友病A小鼠血小板靶向FVIII基因治疗止血效果的影响
本研究在血友病A小鼠中评估抗血小板药物对血小板靶向FVIII(2bF8)基因治疗止血效果的影响。结果显示阿司匹林、氯吡格雷及αIIbβ3阻断抗体Leo.H4均损害体内止血,但氯吡格雷治疗下血小板-FVIII仍优于血浆源性FVIII。
要点
- 抗血小板药物均削弱血小板-FVIII介导的体内止血功能。
- 氯吡格雷治疗小鼠失血量较对照增加10至14倍,但仍优于FVIIInull对照。
- 氯吡格雷治疗下血小板-FVIII止血效果仍优于血浆源性FVIII。
核心结论
- 血小板聚集对血小板-FVIII的止血效能至关重要,抗血小板药物会削弱其功能。
- 尽管抗血小板药物有影响,血小板-FVIII仍优于血浆源性FVIII,提示其临床潜力及需考虑联合用药。
研究设计与样本
- 使用2bF8Tg血友病A小鼠模型,其血小板在αIIb启动子控制下表达FVIII。
- 小鼠分别接受阿司匹林、氯吡格雷或αIIbβ3阻断抗体Leo.H4处理。
- 通过尾部出血模型和体外实验评估止血功能。
主要发现
- 所有抗血小板药物均损害血小板-FVIII介导的体内止血。
- Leo.H4在尾尖和尾静脉横断损伤模型中导致严重出血,与其抑制血小板聚集一致。
- 氯吡格雷治疗小鼠失血量较对照增加10至14倍,出血时间延长,但仍优于FVIIInull对照。
- 氯吡格雷治疗下,血小板-FVIII尽管仅具有正常FVIII活性的24%,止血效果仍优于血浆源性FVIII。
- 阿司匹林也损害止血但程度较轻;体外旋转血栓弹力图和全血凝血酶生成实验未显示阿司匹林或氯吡格雷治疗与对照间的显著差异。
临床怎么用
- 未来应用血小板靶向FVIII基因治疗时,需评估合并抗血小板药物对止血效果的影响。
- 氯吡格雷治疗下血小板-FVIII仍可能优于血浆源性FVIII,但需临床验证。
局限性
- 研究为小鼠模型,结果需在人体中验证。
- 体外旋转血栓弹力图和全血凝血酶生成实验可能无法完全反映血小板-FVIII的动态变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Platelet-targeted factor VIII (FVIII) (2bF8) gene therapy offers promising hemostatic correction in hemophilia A (HA), even in the presence of FVIII inhibitors. Because platelet-derived FVIII is released from platelet α-granules upon activation at injury sites, it is essential to evaluate whether antiplatelet agents would compromise its therapeutic efficacy. Here, we investigated the effect of antiplatelet agents on the efficacy of platelet-FVIII in HA mice. 2bF8Tg mice express FVIII in platelets controlled by the αIIb promoter and were treated with aspirin, clopidogrel, or the αIIbβ3-blocking antibody Leo.H4. Hemostatic function was evaluated through tail-bleeding models and in vitro assays. We found that all antiplatelet agents impaired platelet-FVIII-mediated hemostasis in vivo. Leo.H4 treatment caused severe bleeding in both the tail tip and tail vein transection injury models, consistent with its inhibition of platelet aggregation. Clopidogrel-treated 2bF8Tg mice exhibited 10 to 14 times more blood loss than controls, with extended bleeding; however, they still showed improvement compared to FVIIInull controls. Notably, platelet-FVIII retained superior efficacy compared to plasma-derived FVIII in clopidogrel-treated mice, despite having only 24% of normal FVIII activity. Aspirin also impaired hemostasis but to a lesser extent. In vitro rotational thromboelastometry and whole-blood thrombin generation assays showed no significant differences between aspirin- or clopidogrel-treated and control mice, suggesting that these assays may not fully capture platelet-FVIII dynamics. Our results indicate that platelet aggregation is crucial for the efficacy of platelet-FVIII. Although antiplatelet agents hinder its function, platelet-FVIII remains preferable to plasma-FVIII, highlighting its clinical potential and the importance of considering concomitant therapies in future applications.
引用
- Yu H, Schroeder JA, Mattson JG, et al. Impact of antiplatelet therapy on the hemostatic efficacy of platelet-targeted FVIII gene therapy in hemophilia A mice. Blood Adv. 2026. PMID: 41529228. doi:10.1182/bloodadvances.2025017921
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。